Transition Therapeutics rises on drug deal with Elan

globeandmail.com : Transition Therapeutics rises on drug deal with Elan: "Transition Therapeutics Inc. is teaming up with Dublin-based Elan Corp. to develop a new drug against Alzheimer's disease, in a deal that could land the Canadian company $200-million (U.S.).

The collaboration announced Wednesday covers development and commercialization of Toronto-based Transition's therapeutic agent AZD-103."